Cepheid CE marks one-hour screening test for MRSA
This article was originally published in Clinica
Executive Summary
Cepheid has CE marked its Xpert MRSA/SA nasal test for sale in Europe, and has simultaneously launched the test in "all European countries". It detects both methicillin-resistant and -sensitive Staphylococcus aureus (MRSA and SA, respectively) in less than an hour. Conventional lab culture tests take at least 24 hours. The diagnostic is the first on-demand molecular presurgical screening test for the simultaneous detection of both pathogens, the Sunnyvale, California firm claims. It is available on Cepheid's GeneXpert system.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.